Toronto, Ontario--(Newsfile Corp. - July 9, 2024) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") a leading developer of needle-free devices to administer therapeutics subcutaneously, is pleased to announce that it has formed a three-way partnership with Wholehealth Pharmacy Partners ("Wholehealth") and Sol-Millennium Medical Group ("Sol-M") to develop retail pharmacy training materials aimed at enhancing sales through major pharmacy chains in Canada.

Training pharmacy staff is critical to sales growth & market penetration as the pharmacist serves as a key healthcare professional supporting patient adoption of the InsuJet^TM technology. With educational materials and training, pharmacists can access patient training reimbursement fees, ensuring incentive alignment for the healthcare professional and active support for patient adoption.

With the tagline "Pharmacists supporting Pharmacists", Wholehealth is a respected provider of banner services, educational resources, and training for the pharmacy community in Canada. NuGen, Sol-M, and Wholehealth are committed to delivering the best possible program of training and support to ensure a successful rollout of the InsuJet^TM to major pharmacy retail chains in Canada, with the launch scheduled to start in September 2024.

NuGen's CEO, Ian Heynen commented: "I am delighted to be partnering with an expert like Wholehealth Pharmacy Partners to accelerate Pharmacist adoption of the InsuJet^TM in Canada. With professional pharmacist training and the combined commercial efforts of NuGen and Sol-M, we are fully prepared for a successful commercial launch into the major Canadian pharmacy chains in Q3."

About Wholehealth

Wholehealth is a Canadian pharmacy banner established in 2016, with 240+ locations nationwide. Wholehealth provides expert clinical, operational, and purchasing support to independent pharmacies, and is a leader in developing education and training resources for Canadian pharmacists. Through its innovative services, Wholehealth aims to leverage evidence-based practices to enhance patient care, health equity, and community pharmacy engagement. For more information, visit www.wholehealthpharmacy.ca.

About NuGen

NuGen is a leading developer of needle-free devices to administer therapeutics subcutaneously.

The Company is marketing and selling its next-generation InsuJet™ needle-free injection system designed to improve the lives of millions of diabetics.

InsuJet™ is approved for sale in 42 countries around the world.

About Sol-M

Sol-M is one of the world's largest manufacturers of needles and syringes. It is vertically integrated with locations across the globe. Sol-Millennium's innovative technology helps positive patient outcomes, saves on medication, and enhances both clinician and patient experience. With an international sales team dedicated to delivering knowledge and outstanding customer service, Sol-Millennium's goal is to partner with those in healthcare, focusing on a healthier tomorrow.

For further information, please visit:

Websites: www.insujet.com, www.nugenmd.com and www.solm.com/insujet/

Instagram: @NuGenMD

Twitter: @NuGenMD

LinkedIn: https://www.linkedin.com/company/nugenmd/
and www.linkedin.com/company/sol-millennium-medical-group/

For further information, please contact:

Tony Di Benedetto
Executive Chairman
(416) 791-9399
This email address is being protected from spambots. You need JavaScript enabled to view it.

Ian Heynen
CEO
(416) 560-1019
This email address is being protected from spambots. You need JavaScript enabled to view it.

To arrange a media interview with NuGen, please contact:

Morna Gorman
(416) 553-1732
This email address is being protected from spambots. You need JavaScript enabled to view it.

Notice Regarding Forward-Looking Information

Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accept responsibility for the adequacy or accuracy of this release.

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. These forward-looking statements are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. The forward-looking information contained herein is given as of the date hereof and the Company assumes no responsibility to update or revise such information to reflect new events or circumstances, except as required by law.